Active cocaine use is associated with lack of HIV-1 virologic suppression independent of nonadherence to antiretroviral therapy: Use of a rapid screening tool during routine clinic visits

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 25, Issue 1, 2013, Pages 109-117

  Rasbach, Daniel A ^a   Desruisseau, Andrew J ^b   Kipp, Aaron M ^a,c   Stinnette, Samuel ^a   Kheshti, Asghar ^a   Shepherd, Bryan E ^a   Sterling, Timothy R ^a   Hulgan, Todd ^a   Mcgowan, Catherine C ^a   Qian, Han Zhu ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiretroviral therapy; Cocaine; Drug use; HIV 1 virologic suppression; Marijuana

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CANNABIS; COCAINE; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE;

ADULT; AMBULATORY CARE; ANTI-HIV AGENTS; COCAINE-RELATED DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; ODDS RATIO; PATIENT COMPLIANCE; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84870953560     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540121.2012.687814     Document Type: Article

References (41)

1. Arnsten, J.H., Demas, P.A., Grant, R.W., Gourevitch, M.N., Farzadegan, H., Howard, A.A., & Schoenbaum, E.E. (2002). Impact ofactive drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. Journal of General Internal Medicine, 17(5), 377-381.
2. Bagasra, O., & Pomerantz, R.J. (1993). Human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells in the presence ofcocaine. Journal of Infectious Diseases, 168(5), 1157-1164.
3. Baum, M.K., Rafie, C., Lai, S., Sales, S., Page, B., & Campa, A. (2009). Crack-cocaine use accelerates HIV disease progression in a cohort ofHIV-positive drug users. Journal of Acquired Immune Deficiency Syndromes, 50, 93-99.
4. Berg, K.M., Wilson, I.B., Li, X., & Arnsten, J.H. (2012). Comparison ofantiretroviral adherence questions. AIDS and Behavior, 16(2), 461-468.
5. Bogart, L.M., Kelly, J.A., Catz, S.L., & Sosman, J.M. (2000). Impact ofmedical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. Journal of Acquired Immune Deficiency Syndromes, 23(5), 396-404.
6. Bouhnik, A.D., Preau, M., Schiltz, M.A., Peretti-Watel, P., Obadia, Y., Lert, F., ... VESPA Group. (2006). Unsafe sex with casual partners and quality of life among HIV-infected gay men: Evidence from a large representative sample ofoutpatients attending French hospitals (ANRS-EN12-VESPA). Journal of Acquired Immune Deficiency Syndromes, 42(5), 597-603.
7. Cabral, G.A. (2006). Drugs ofabuse, immune modulation, and AIDS. Journal of Neuroimmune Pharmacology, 1, 280-295.
8. CDC. (2008). HIV Prevalence Estimates-United States, 2006. MMWR, 57(39), 1073-1076.
9. Chesney, M.A., Ickovics, J.R., Chambers, D.B., Gifford, A.L., Neidig, J., Zwickl, B., & Wu, A.W. (2000). Selfreported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments. AIDS Care, 12(3), 255-266.
10. Cofrancesco, J., Jr., Scherzer, R., Tien, P.C., Gilbert, C.L., Southwell, H., Sidney, S., ... Grunfeld, C. (2008). Illicit drug use and HIV treatment outcomes in a US cohort. AIDS, 22(3), 357-365.
11. Cook, J.A., Burke-Miller, J.K., Cohen, M.H., Cook, R.L., Vlahov, D., Wilson, T.E., ... Grey, D.D. (2008). Crack cocaine, disease progression, and mortality in a multicenter cohort ofHIV-1 positive women. AIDS, 22, 1355-1363.
12. Deschamps, A.E., De Geest, S., Vandamme, A., Bobbaers, H., Peetermans, W.E., & Van Wijngaerden, E. (2008). Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care and STDs, 22(9), 735-743.
13. Di Franco, M.J., Sheppard, H.W., Hunter, D.J., Tosteson, T.D., & Ascher, M.S. (1996). The lack ofassociation of marijuana and other recreational drugs with progression to AIDS in the San Francisco Men's Health Study. Annals of Epidemiology, 6(4), 283-289.
14. Hessol, N.A., Kalinowski, A., Benning, L., Mullen, J., Young, M., Palella, F., ... Cohen, M.H. (2007). Mortality among participants in the multicenter AIDS cohort study and the women's interagency HIV study. Clinical Infectious Diseases, 44(2), 287-294.
15. Hinkin, C.H., Barclay, T.R., Castellon, S.A., Levine, A.J., Durvasula, R.S., Marion, S.D., ... Longshore, D. (2007). Drug use and medication adherence among HIV-1 infected individuals. AIDS and Behavior, 11(2), 185-194.
16. Hogg, R.S., Heath, K., Bangsberg, D., Yip, B., Press, N., O'Shaughnessy, M.V., & Montaner, J.S. (2002). Intermittent use oftriple-combination therapy is predictive ofmortality at baseline and after 1 year off ollow-up. AIDS, 16(7), 1051-1058.
17. Johnson, M., Sabin, C., & Girardi, E. (2010). Definition and epidemiology oflate presentation in Europe. Antiviral Therapy, 15(Suppl. 1), 3-8.
18. Kapadia, F., Vlahov, D., Donahoe, R.M., & Friedland, G. (2005). The role ofsubstance abuse in HIV disease progression: Reconciling differences from laboratory and epidemiologic investigations. Clinical Infectious Diseases, 41(7), 1027-1034.
19. Kipp, A.M., Desruisseau, A.J., & Qian, H. (2011). Non-injection drug use and HIV disease progression in the era ofcombination antiretroviral therapy. Journal of Substance Abuse Treatment, 40(4), 386-396.
20. Lemly, D.C., Shepherd, B.E., Hulgan, T., Rebeiro, P., Stinnette, S., Blackwell, R.B., ... Raffanti, S.P. (2009). Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. Journal of Infectious Diseases, 199(7), 991-998.
21. Lima, V.D., Harrigan, R., Bangsberg, D.R., Hogg, R.S., Gross, R., Yip, B., & Montaner, J.S. (2009). The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. Journal of Acquired Immune Deficiency Syndromes, 50(5), 529-536.
22. Lucas, G.M., Cheever, L.W., Chaisson, R.E., & Moore, R.D. (2001). Detrimental effects of continued illicit drug use on the treatment ofHIV-1 infection. Journal of Acquired Immune Deficiency Syndromes, 27(3), 251-259.
23. Lucas, G.M., Gebo, K.A., Chaisson, R.E., & Moore, R.D. (2002). Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS, 16(5), 767-774.
24. McGowan, C.C., Weinstein, D.D., Samenow, C.P., Stinnette, S.E., Barkanic, G., Rebeiro, P.F., ... Hulgan, T. (2011). Drug use and receipt ofhighly active antiretroviral therapy among HIV-infected persons in two U.S.clinic cohorts. PLoS One, 6(4), e18462.
25. Mills, E.J., Nachega, J.B., Bangsberg, D.R., Singh, S., Rachlis, B., Wu, P., ... Cooper, C. (2006). Adherence to HAART: A systematic review ofdeveloped and developing nation patient-reported barriers and facilitators. PLoS Medicine, 3(11), e438.
26. Mocroft, A., Ledergerber, B., Katlama, C., Kirk, O., Reiss, P., d'Arminio Monforte, A., ... EuroSIDA study group. (2003). Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet, 362(9377), 22-29.
27. Nair, M.P., Chadha, K.C., & Hewitt, R.G. (2000). Cocaine differentially modulates chemokine production by mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients. Clinical and Diagnostic Laboratory Immunology, 7(1), 96-100.
28. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2011. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1-167. Retrieved January 15, 2012, from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
29. Purcell, D.W., Moss, S., Remien, R.H., Woods, W.J., & Parsons, J.T. (2005). Illicit substance use, sexual risk, and HIV-positive gay and bisexual men: Differences by serostatus ofcasual partners. AIDS, 19(Suppl. 1), S37-S47.
30. Qian, H.Z., Stinnette, S.E., Rebeiro, P.F., Kipp, A.M., Shephered, B.E., Samenow, C.P., ... Sterling, T.R. (2011). The relationship between injection and noninjection drug use and HIV disease progression. Journal of Substance Abuse Treatment, 41(1), 14-20.
31. Simoni, J.M., Kurth, A.E., Pearson, C.R., Pantalone, D.W., Merrill, J.O., & Frick, P.A. (2006). Self-report measures ofantiretrovi ral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS and Behavior, 10, 227-245.
32. Sohler, N.L., Wong, M.D., Cunningham, W.E., Cabral, H., Drainoni, M.L., & Cunningham, C.O. (2007). Type and pattern ofillicit drug use and access to health care services for HIV-infected people. AIDS Patient Care and STDs, 21(Suppl. 1), S68-S76.
33. Sullivan, P.S., Nakashima, A.K., Purcell, D.W., & Ward, J.W. (1998). Geographic differences in noninjection and injection substance use among HIV-seropositive men who have sex with men: Western United States versus other regions. Supplement to HIV/AIDS Surveillance Study Group. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 19(3), 266-273.
34. Tashkin, D.P. (2005). Evidence implicating cocaine as a possible risk factor for HIV infection. Journal of Immunology, 147(1-2), 26-27.
35. Toobert, D.J., Hampson, S.E., & Glasgow, R.E. (2000). The summary ofdiabetes self-care activities measure: Results from 7 studies and a revised scale. Diabetes Care, 23(7), 943-950.
36. Tucker, J.S., Burnam, M.A., Sherbourne, C.D., Kung, F.Y., & Gifford, A.L. (2003). Substance use and mental health correlates ofnonadherence to antiretroviral medications in a sample ofpatients with human immunodeficiency virus infection. American Journal of Medicine, 114(7), 573-580.
37. Turner, B.J., Fleishman, J.A., Wenger, N., London, A.S., Burnam, M.A., Shapiro, M.F., ... Bozzette, S.A. (2001). Effects of drug abuse and mental disorders on use and type ofantiretroviral therapy in HIV-infected persons. Journal of General Internal Medicine, 16(9), 625-633.
38. Walensky, R.P., Paltiel, A.D., Losina, E., Mercincavage, L.M., Schackman, B.R., Sax, P.E., ... Freedberg, K.A. (2006). The survival benefits ofAIDS treatment in the United States. Journal of Infectious Diseases, 194(1), 11-19.
39. Weintrob, A.C., Grandits, G.A., Agan, B.K., Ganesan, A., Landrum, M.L., Crum-Cianflone, N.F., ... IDCRP HIV Working Group. (2009). Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. Journal of Acquired Immune Deficiency Syndromes, 52(5), 574-580.
40. Wilson, I.B., Carter, A.I., & Berg, K.M. (2009). Improving the self-report of HIV antiretroviral medication adherence: Is the glass halff ull or half empty? Current HIV/AIDS Reports, 6(4), 177-186.
41. Wood, E., Montaner, J.S., Yip, B., Tyndall, M.W., Schechter, M.T., O'Shaughnessy, M.V., & Hogg, R.S. (2003). Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. Canadian Medical Association Journal, 169(7), 656-661.